common.study.topics.clinical

Testing Experimental Schizophrenia Medication

common.study.values.description

“Study of CAD-9303 in Subjects With Schizophrenia”

This study will consist of Single Ascending Dose (SAD) cohorts that will be randomized, double blind, and placebo-controlled to assess the safety, tolerability, and pharmacokinetics of CAD-9303. The first SAD cohort will be in healthy volunteer subjects. The remaining cohorts will be in participants with schizophrenia.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Drug - CAD-9303

Capsules filled with CAD-9303 from 3 mg up to 1000 mg.

Drug - Placebos

Capsules

participant.views.study.view.additional

participant.views.study.view.scientific-title

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Effects on Neurophysiological Biomarkers of CAD-9303 Oral Treatment in Subjects With Schizophrenia and Normal Healthy Volunteers

common.study.values.clinical-trial-id

NCT04306146

participant.views.study.view.id

aQWVMd